After three decades at the forefront of the fight to get drugs studied and labeled for children, the Academy is poised to celebrate a victory on two fronts. Last year, a provision for pediatric studies of drugs was included in AAP-supported legislation passed by Congress, and at press time, the Food and Drug Administration (FDA) was preparing to issue final regulations to increase pediatric use information for drugs and biologics.
"The legislation and proposed regulations represent the best stimulation to increase the number of drugs for children in decades," said Robert M. Ward, M.D., chair of the AAP Committee on Drugs (COD). "A lot of credit should go to Congress and the current administration for championing this issue. Children will truly benefit from it."